SVSubhash Varma

Subhash Varma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Subhash Varma has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pathogenic Mutations in the Tumor Microenvironment Drive Tumor Progression in Diffuse Large B-Cell Lymphoma Through Tumor–Stroma Cross-Talk

    by Vaishali Aggarwal, Radhika Srinivasan, Amanjit Bal, Pankaj Malhotra, Subhash Varma, Ashim Das

    Background: Diffuse Large B-cell Lymphoma (DLBCL) is a biologically heterogeneous subtype of non-Hodgkin’s lymphoma (NHL), accounting for 30–40% of cases worldwide. Despite the incorporation of rituximab into standard chemo-immunotherapy regimen, approximately one-third of patients present with relapsed or refractory disease, implicating the need for improved prognostic markers and therapeutic targets. Gene expression profiling successfully classified DLBCL into Germinal Center B-cell-like (GCB) and non-GCB subtypes, which differ in genetic alterations, response to therapy, and clinical outcome. While intrinsic tumor biology has been extensively studied, the contribution of the tumor microenvironment (TME) to disease progression and therapeutic resistance still remains incompletely understood. Methods: In this study, we investigated the mutational landscape of stromal-related genes in DLBCL and evaluated their impact on gene expression, downstream signaling pathways, and tumor progression. Results: A total of 176 DLBCL patients were screened, of which 113 were enrolled based on availability of complete clinical data. The cohort demonstrated male predominance (male:female ratio: 2.1:1), advanced disease stage in 72.6% of patients, and elevated serum lactate dehydrogenase levels in 57.5%. Based on immunohistochemistry, 43.4% cases were classified as GCB-DLBCL and 56.6% as non-GCB DLBCL. Although the International Prognostic Index (IPI) retained prognostic significance for event-free survival (EFS) and overall survival (OS), considerable heterogeneity was observed within similar risk groups. Whole-exome sequencing (WES) uncovered recurrent somatic mutations in key oncogenic and epigenetic regulators, including TNFAIP3, NFIB, NOTCH1, TSC2, EZH2, EP300, KMT2D, and B2M, with subtype-specific distribution. Pathway enrichment analysis implicated role of Notch, Wnt, mTOR, JAK-STAT, TGF-β, and antigen-presentation pathways. Comprehensive WES analysis identified multiple novel mutations in genes associated with the stromal/extracellular matrix with distinct patterns in GCB and non-GCB DLBCL, accompanied by concordant alterations in gene expression profiles, suggesting functional relevance within the TME. Functional validation through primary cell culture demonstrated significantly elevated Th2 (IL-4, IL-6, IL-10) and Th17 (IL-17) cytokines in co-cultures containing both neoplastic cells and stromal components, underscoring the role of TME in DLBCL progression. Conclusions: Taken together, this study provides novel insights into stromal mutational signatures and cytokine-mediated tumor–stroma interactions, offering potential prognostic biomarkers and therapeutic targets for the improved management of DLBCL.

  • A homozygous KLF1 gene mutation presenting as mild Thalassemia Intermedia unraveled by targeted Next Generation Sequencing

    by Neetu Rani, Manu Jamwal, Jasbir Kaur, Pankaj Malhotra, Prashant Sharma, Arindam Maitra, Ranvir Singh, Subhash Varma, Reena Das

    The krupple-like factor 1 (KLF1) is a crucial transcription factor that is responsible for the proper maturation of the erythroid cells. Recent studies have demonstrated that mutations in KLF1 gene may lead to increased fetal hemoglobin (HbF) and reduced or borderline hemoglobin A2 (HbA2) levels. Increased HbF levels and concomitant α-thalassemia are two main modifiers that can ameliorate the clinical and hematological severity of β-thalassemia. Mutations in KLF1 have been found in association with β thalassemia. DNA was extracted with QIAmp DNA Blood kit and quantified spectrophotometrically. Gap PCR was used to screen common HPFH deletions and Sanger’s sequencing was done to screen β-globin (HBB) mutations. Libraries were prepared using TruSight One sequencing panel and sequenced on MiSeq Sequencing System. MiSeq Reporter and Variant Studio were used for data analysis. A 56 years male presented with splenomegaly and unconjugated hyperbilirubinemia with normal hematological indices. Hemoglobin high performance liquid chromatography revealed 72.3% HbF, 0.5% HbA2 and 25.2% HbA0. Patient was found to be clinically consistent with mild TI. No mutation/s in HBB was found by Sangers sequencing. Hereditary Persistence of Fetal Hemoglobin (HPFH) deletions [HPFH1, HPFH2, HPFH3, ChineseG deletion, Asian-Indian inversion-deletion] were also found to be negative. Targeted resequencing revealed a novel homozygous probably causative mutation in KLF1 [c. 943C>T (p.Arg301Cys)]. This mutation was found to be probably damaging via PolyPhen2 and SIFT. The patient's son showed 5% HbF with heterozygous mutation. This is the first report from India where a homozygous mutation in KLF1 gene is implicated with high HbF in a patient with TI. Thus, mutations which affect the activity of KLF1 gene may lead to high level of fetal hemoglobin in patients presenting as TI with no HBB mutations. The krupple-like factor 1 (KLF1) is a crucial transcription factor that is responsible for the proper maturation of the erythroid cells. Recent studies have demonstrated that mutations in KLF1 gene may lead to increased fetal hemoglobin (HbF) and reduced or borderline hemoglobin A2 (HbA2) levels. Increased HbF levels and concomitant α-thalassemia are two main modifiers that can ameliorate the clinical and hematological severity of β-thalassemia. Mutations in KLF1 have been found in association with β thalassemia. DNA was extracted with QIAmp DNA Blood kit and quantified spectrophotometrically. Gap PCR was used to screen common HPFH deletions and Sanger’s sequencing was done to screen β-globin (HBB) mutations. Libraries were prepared using TruSight One sequencing panel and sequenced on MiSeq Sequencing System. MiSeq Reporter and Variant Studio were used for data analysis. A 56 years male presented with splenomegaly and unconjugated hyperbilirubinemia with normal hematological indices. Hemoglobin high performance liquid chromatography revealed 72.3% HbF, 0.5% HbA2 and 25.2% HbA0. Patient was found to be clinically consistent with mild TI. No mutation/s in HBB was found by Sangers sequencing. Hereditary Persistence of Fetal Hemoglobin (HPFH) deletions [HPFH1, HPFH2, HPFH3, ChineseG deletion, Asian-Indian inversion-deletion] were also found to be negative. Targeted resequencing revealed a novel homozygous probably causative mutation in KLF1 [c. 943C>T (p.Arg301Cys)]. This mutation was found to be probably damaging via PolyPhen2 and SIFT. The patient's son showed 5% HbF with heterozygous mutation. This is the first report from India where a homozygous mutation in KLF1 gene is implicated with high HbF in a patient with TI. Thus, mutations which affect the activity of KLF1 gene may lead to high level of fetal hemoglobin in patients presenting as TI with no HBB mutations.


  • Safety and efficacy of a single dose of Anti-D (WinRho®) in severe thrombocytopenia secondary to dengue virus infection

    by Ashish Bhalla, AshokKumar Pannu, Mayank Singhal, Vikas Suri, Nusrat Shafiq, Subhash Varma

  • Use of Surrogate Samples to Monitor pH During High dose Methotrexate Therapy

    by Uday Yanamandra, Pooja Chauhan, Deepesh Lad, Alka Khadwal, Gaurav Prakash, Subhash Varma, Pankaj Malhotra


  • Knuckle Pigmentation: A Clue to Systemic Illness

    by Arjun Lakshman, Ram V. Nampoothiri, Sreejesh Sreedharanunni, Pankaj Malhotra, Subhash Varma


  • Is 18F-FDG-PET/CT a good MRD marker in patients with multiple myeloma? Comparison and correlation with biochemical markers/flowcytometry.

    by Uday Yanamandra, B.R. Mittal, Man Upadesh, Arun Reddy, Praveen Sharma, Kanhaiya Agarwal, Alka Khadwal, Gaurav Prakash, Neelam Varma, Subhash Varma, et al.

    8029 Background: Multiple myeloma is a heterogenous disorder with varied responses to chemotherapy. The response criteria are defined based on biochemical assays, bone marrow (BM) examination, flowcytometry and molecular assays. Lately PET/CT is employed in MRD analysis. We aimed at studying the correlation of 18F-FDG-PET/CT with various biochemical markers, bone marrow plasma cells, and flowcytometry MRD analysis as a cross-sectional comparison at a given time point in patients post myeloma therapy. Methods: This is a single-center non-interventional study as part of PIPET-M trial. Patients of multiple myeloma underwent 18F-FDG-PET/CT, biochemical evaluation including (SPEP, UPEP, SIFE, SFLC, β2M, LDH) and BM examination (for plasma cells percentage and flowcytometry for MRD) as part of end of treatment analysis. Patients were included after induction chemotherapy, pre-autologous transplant (within 30 days) or post-transplant (Day 100) for analyzing efficacy of therapy. PET- positivity was based on the PIPET-M staging (A validated staging system developed by the authors). Results: A total of 72 patients were screened of which 52 patients underwent PET/CT, biochemical evaluation including (SPEP, UPEP, SIFE, SFLC, β2M and LDH) and bone marrow examination. Concurrent flowcytometry for MRD was done only in 11 patients. PET positivity had no relation with the pre transplant biochemical markers (SPEP, UPEP, SIFE) [χ2 - (1, 53)-0.34, p-0.56; (1, 52) - 2.18, p-0.14; (1, 52) – 0.32, p-0.57 respectively] or BM plasma cell percentage (p-0.64). In PET positive patients, β2M and LDH were higher (p - 0.032), whereas SFLC ratio though higher was not statistically significant (p-0.61). There was a good agreement between PET positivity and MRD by flowcytomtery (Cohen’s κ - 0.662, p < 0.001). Conclusions: 18F-FDG-PET/CT is a good marker for MRD analysis with good agreement with flowcytometry and disease activity markers such as β2M/ LDH. Its poor correlation with SPEP, UPEP, SIFE and BM plasma cell percentage can be secondary to undetectable levels of these markers in many patients (~ 84%) after therapy. A comparison of these markers for prognosticating PFS/OS is further warranted. Clinical trial information: U1111-1177-8850, REF/2015/12/010356.

  • Cholestasis in a Patient of Multiple Myeloma: A Rare Occurrence of Bortezomib Induced Liver Injury

    by Ankur Jain, Pankaj Malhotra, Vikas Suri, Subhash Varma, Ashim Das, Suvradeep Mitra


  • Molecular response assessment at 3 months time point is better in late chronic phase chronic myeloid leukemia patients

    by Pankaj Malhotra, Santosh Chikkodi, Shano Naseem, Alka Khadwal, Gaurav Prakash, Kamal Kant Sahu, Neelam Varma, Subhash Varma, Savita Kumari, Vikas Suri

  • Effect of steroids on the activation status of platelets in patients with Immune thrombocytopenia (ITP)

    by Preeti Bhoria, Saniya Sharma, Neelam Varma, Pankaj Malhotra, Subhash Varma, Manni Luthra-Guptasarma

    The activation status of platelets in Immune Thrombocytopenia (ITP) patients--which is still somewhat controversial--is of potential interest, because activated platelets tend to aggregate (leading to excessive clotting or thromboembolic events) but cannot do so when platelet numbers are low, as in ITP. Although corticosteroids are the first line of therapy in ITP, the effect of steroids on activation of platelets has not been evaluated so far. We examined the status of platelet activation (with and without stimulation with ADP) in ITP patients, at the start of therapy (pre-steroid treatment, naive) and post-steroid treatment (classified on the basis of steroid responsiveness). We used flow cytometry to evaluate the levels of expression of P-selectin, and PAC-1 binding to platelets of 55 ITP patients and a similar number of healthy controls, treated with and without ADP. We found that platelets in ITP patients exist in an activated state. In patients who are responsive to steroids, the treatment reverses this situation. Also, the fold activation of platelets upon treatment with ADP is more in healthy controls than in ITP patients; treatment with steroids causes platelets in steroid-responsive patients to become more responsive to ADP-activation, similar to healthy controls. Thus steroids may cause changes in the ability of platelets to get activated with an agonist like ADP. Our results provide new insights into how, and why, steroid therapy helps in the treatment of ITP.


  • Outcomes of splenectomy versus cladribine for hairy cell leukemia in resource limited settings

    by Deepesh P. Lad, Pankaj Malhotra, Alka Khadwal, Gaurav Prakash, Vikas Suri, Savita Kumari, Sanjay Jain, Reena Das, Neelam Varma, Subhash Varma

    Treatment for hairy cell leukemia (HCL) has evolved over the years from splenectomy to interferon to purine analogs to monoclonal antibody based therapy [1]. Until three decades ago, splenectomy wa...